Method and solution for treating glaucoma
AssigneeNew England Medical Center Hospitals, Inc.
InventorBernard Schwartz
Life of this patent
Estimating the term…
Abstract
A method for treating glaucoma consisting of exposing the eye to a corticosteroid and a beta adrenergic agent to the eye which acts to decrease ocular pressure. Useful adrenergic agents include beta agonists antagonists, including, for example, epinephrine, dipivalyl epinephrine, betaxolol, levobunolol, and timolol. Useful steroids, which are preferably applied topically, include dexamethasone, prednisolone, cortisone, and triamcinolone. The beta adrenergic agent is administered at a concentration between about 10% and 20% of the concentration that the agent is administered in its normal use. The corticosteroid is administered at a concentration between 5% and 10% of the concentration that the corticosteroid is administered in its normal use.
Claims5
A method for treating elevated intraocular pressure in a mammalian eye comprising:
- administering to the eye a therapeutically effective amount of a corticosteroid and a beta adrenergic agent,
- said corticosteroid selected from the group consisting of dexamethasone having a concentration from 0.0005 to 0.01%, prednisolone having a concentration from 0.005 to 0.1%, hydrocortisone having a concentration from 0.0025 to 0.05%, cortisone having a concentration from 0.0125 to 0.25%, fluorometholone having a concentration from 0.0005 to 0.01%, betamethasone having a concentration from 0.0005 to 0.01%, methyl prednisolone having a concentration from 0.04 to 0.8%, triamcinolone having a concentration of 0.0005 to 0.01% and their physiologically acceptable salts;
- said beta adrenergic agent selected from the group consisting of epinephrine having a concentration from 0.05 to 0.1%, cartelol having a concentration ranging fron 0.1 to 0.4%, dipivalyl epinephrine having a concentration from 0.01 to 0.02%, betaxolol having a concentration from 0.05 to 0.1%, timolol having a concentration from 0.025 to 0.1%, levobunolol having a concentration from 0.05 to 0.1% and their physiologically acceptable salts;
- the concentration of said corticosteroid and said beta adrenergic agent being selected to produce a prolonged decrease in intraocular pressure while minimizing undesirable side effects of said corticosteroid and said beta adrenergic agent.
A solution for treating elevated intraocular pressure in a mammalian eye comprising:
- a corticosteroid selected from the group consisting of dexamethasone having a concentration from 0.0005 to 0.01%, prednisolone having a concentration from 0.005 to 0.1%, hydrocortisone having a concentration from 0.0025 to 0.05%, cortisone having a concentration from 0.0125 to 0.25%, fluorometholone having a concentration from 0.0005 to 0.01%, betamethasone having a concentration from 0.0005 to 0.01%, methyl prednisolone having a concentration from 0.04 to 0.8% triamcinolone having a concentration of 0.0005 to 0.01% and their physiologically acceptable salts;
- a beta adrenergic agent selected from the group consisting of epinephrine having a concentration from 0.05 to 0.1%, cartelol having a concentration ranging from 0.1 to 0.4% dipivalyl epinephrine having a concentration from 0.01 to 0.02%, betaxolol having a concentration from 0.05 to 0.1%, timolol having a concentration from 0.025 to 0.1%, levobunolol having a concentration from 0.05 to 0.1% and their physiologically acceptable salts;
- the concentration of said corticosteroid and said beta adrenergic agent being selected to produce a prolonged decrease in intraocular pressure while minimizing undesirable side effects of said corticosteroid and said beta adrenergic agent.
Dependencies are inferred from the claim text.